TT 701

Drug Profile

TT 701

Alternative Names: LY 2452473; OPK 88004

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Brigham and Women's Hospital; Dana-Farber Cancer Institute; Transition Therapeutics
  • Class Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Benign prostatic hyperplasia; Erectile dysfunction; Prostate cancer

Most Recent Events

  • 27 Nov 2017 Phase-II clinical trials in Benign prostatic hyperplasia in USA (PO)
  • 27 Nov 2017 Pharmacodynamics data from preclinical studies in Benign prostatic hyperplasia released by Transition Therapeutics
  • 01 Mar 2017 Transition Therapeutics plans a phase II trial for Benign prostatic hypertrophy in 2H 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top